Trials / Withdrawn
WithdrawnNCT00487799
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects hospitalized with symptomatic acute decompensated heart failure (ADHF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ularitide |
Timeline
- First posted
- 2007-06-19
- Last updated
- 2009-07-20
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00487799. Inclusion in this directory is not an endorsement.